Results 21 to 30 of about 28,618 (205)
Медицинская иммунология, 2022 Purinergic signaling modulates systemic and local inflammatory responses in immune-mediated and autoimmune diseases, including psoriasis. Extracellular ATP is an important factor of purinergic regulation, and its levels are regulated by catalytic effects
D. G. Kuptsova +5 more
doaj +1 more source
Targeting CD39 as a Therapeutic for Cancer Immunotherapy. [PDF]
Expert Rev Mol MedAbstract CD39 plays a pivotal role in the ATP-to-adenosine signalling pathway, serving as a critical mediator of immune suppression within the tumour microenvironment. Increasing preclinical evidence indicates that its inhibition can restore antitumour immunity and improve the efficacy of established treatments.
Li Z, Xu W, Kwok HF.
europepmc +3 more sources
CD39 and CD73 in immunity and inflammation [PDF]
Trends in Molecular Medicine, 2013 The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced ...
Luca, Antonioli +3 more
openaire +2 more sources
OncoImmunology, 2021 The inhibitory receptor TIGIT, as well as theectonucleotidases CD39 and CD73 constitute potential exhaustion markers for T cells. Detailed analysis of these markers can shed light into dysregulation of the T-cell response in acute myeloid leukemia (AML ...
F. Brauneck +11 more
doaj +1 more source
Journal for ImmunoTherapy of Cancer, 2022 Background An important mechanism, by which cancer cells achieve immune escape, is the release of extracellular adenosine into their microenvironment. Adenosine activates adenosine A2A and A2B receptors on immune cells constituting one of the strongest ...
Julie Pelletier +9 more
doaj +1 more source
Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors [PDF]
Frontiers in Pharmacology, 2020 Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5'-nucleotidase (CD73) to immunosuppressive, cancer-promoting adenosine ...
Laura Schäkel +12 more
openaire +3 more sources
OncoImmunology, 2023 Conventional CD4+ T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood.
Sabrina N. Bossio +17 more
doaj +1 more source
CD39 Is an Ecto-(Ca2+,Mg2+)-apyrase [PDF]
Journal of Biological Chemistry, 1996 CD39, a 70- to 100-kDa molecule expressed primarily on activated lymphoid cells, was previously identified as a surface marker of Epstein Barr virus (EBV)-transformed B cells. In this report, we show that an ecto-(Ca2+,Mg2+)-apyrase activity is present on EBV-transformed B cells, but not on B or T lymphomas.
T F, Wang, G, Guidotti
openaire +2 more sources
CD39 – A bright target for cancer immunotherapy
Biomedicine & Pharmacotherapy, 2022 The ATP-adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumor microenvironment, and cancer immune evasion largely involves the generation of high amounts of immunosuppressive extracellular adenosine (eADO). Consequently, inhibition of eADO-generating enzymes and/or eADO receptors can effectively restore the ...
Shuwei, Guo, Fengfeng, Han, Wei, Zhu
openaire +2 more sources
Human Vaccines & Immunotherapeutics, 2018 The field of immunotherapeutics is living an exceptional time as new antibodies that take brakes off T-cells and unleash them on tumours are being approved by the US-Food and Drug Administration (FDA).
Audrey Hubert, Nabila Seddiki
doaj +1 more source